- Keytruda — Merck’s Keytruda has been approved to treat triple-negative breast cancer in combination with chemotherapy. The drug has now been approved to treat 30 types of cancer.
- Bydureon — AstraZeneca’s Bydureon has been approved to treat Type 2 diabetes in pediatric patients ages 10 years and older.
- Rezurock — Kadmon Pharmaceuticals’ Rezurock has been approved to treat chronic graft-versus-host disease.
- Wegovy — Novo Nordisk’s Wegovy has been approved to treat obesity, the first new drug to treat the condition approved by the FDA in seven years.
- Rylaze — Jazz Pharmaceuticals’ Rylaze has been approved as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the drugs used most commonly for treatment.
- Pradaxa — Boehringer Ingelheim’s Pradaxa has been approved to treat venous thromboembolism, a condition where blood clots form in the veins, in children 3 months to under 12 years old. It is the first FDA-approved blood-thinning medication that children can take by mouth.
- Astepro — Bayer’s Astepro, a nasal antihistamine, has been approved for nonprescription use. Astepro is approved to treat seasonal and perennial allergic rhinitis in adults and children over 6 years.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
